Literature DB >> 20127220

Mycobacterium bovis bacillus Calmette-Guerin treated human cord blood monocyte-derived dendritic cells polarize naïve T cells into a tolerogenic phenotype in newborns.

En-Mei Liu1, Helen K W Law, Yu Lung Lau.   

Abstract

BACKGROUND: As one of the first infectious challenges of life, the impact of neonatal Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccination on the polarization of neonatal T helper subset has not been well defined.
METHODS: We investigated the effect of BCG-treated cord blood (CB) dendritic cells (DCs) on naïve CD4+ T cells polarization compared with that of adult blood DCs.
RESULTS: BCG-treated CB DCs had significantly lower expression of CD83 and a higher ratio of CD47/Fas than BCG-treated adult blood DCs. BCG induced significantly lower IL-12 but relatively higher IL-10 production from CB DCs than adult blood DCs. Moreover, in comparison with BCG-treated adult blood DCs, BCG-treated CB DCs induced higher IL-10 production and cytotoxic T-lymphocyte antigen 4 (CTLA-4) expression, and lower interferon-gamma (IFN-gamma) production from naïve CD4+ T cells. On the other hand, lipopolysaccharide-treated CB DCs had similar capacity as prime naïve CD4+ T cells did to produce higher IFN-gamma, lower IL-10 production, and CTLA-4 expression compared with their adult counterparts.
CONCLUSION: These results suggested that BCG-treated CB DCs might be semi-mature DCs which polarize naïve T cells into a tolerogenic T cell phenotype in newborns.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127220     DOI: 10.1007/s12519-010-0019-0

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


  37 in total

1.  CD47 engagement inhibits cytokine production and maturation of human dendritic cells.

Authors:  C E Demeure; H Tanaka; V Mateo; M Rubio; G Delespesse; M Sarfati
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

2.  Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells.

Authors:  A Langenkamp; M Messi; A Lanzavecchia; F Sallusto
Journal:  Nat Immunol       Date:  2000-10       Impact factor: 25.606

Review 3.  Ontogeny of T lymphocyte function in the neonate.

Authors:  C B Wilson; L Penix; W M Weaver; A Melvin; D B Lewis
Journal:  Am J Reprod Immunol       Date:  1992 Oct-Dec       Impact factor: 3.886

Review 4.  Dendritic cell subsets and toll-like receptors.

Authors:  Hubertus Hochrein; Meredith O'Keeffe
Journal:  Handb Exp Pharmacol       Date:  2008

5.  Enhanced antigen-presenting activity and tumour necrosis factor-alpha-independent activation of dendritic cells following treatment with Mycobacterium bovis bacillus Calmette-Guérin.

Authors:  K D Kim; H G Lee; J K Kim; S N Park; I S Choe; Y K Choe; S J Kim; E Lee; J S Lim
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

6.  The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation.

Authors:  B de Saint-Vis; I Fugier-Vivier; C Massacrier; C Gaillard; B Vanbervliet; S Aït-Yahia; J Banchereau; Y J Liu; S Lebecque; C Caux
Journal:  J Immunol       Date:  1998-02-15       Impact factor: 5.422

7.  Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages.

Authors:  D M Underhill; A Ozinsky; K D Smith; A Aderem
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

8.  CD47 ligation selectively downregulates human interleukin 12 production.

Authors:  M Armant; M N Avice; P Hermann; M Rubio; M Kiniwa; G Delespesse; M Sarfati
Journal:  J Exp Med       Date:  1999-10-18       Impact factor: 14.307

9.  The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells.

Authors:  M Lechmann; D J Krooshoop; D Dudziak; E Kremmer; C Kuhnt; C G Figdor; G Schuler; A Steinkasserer
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

10.  Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses.

Authors:  M Rescigno; V Piguet; B Valzasina; S Lens; R Zubler; L French; V Kindler; J Tschopp; P Ricciardi-Castagnoli
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307

View more
  6 in total

1.  Activation of cord blood myeloid dendritic cells by Trypanosoma cruzi and parasite-specific antibodies, proliferation of CD8+ T cells, and production of IFN-γ.

Authors:  Patricia Rodriguez; Yves Carlier; Carine Truyens
Journal:  Med Microbiol Immunol       Date:  2011-10-29       Impact factor: 3.402

2.  Maturation of innate responses to mycobacteria over the first nine months of life.

Authors:  Muki S Shey; Elisa Nemes; Wendy Whatney; Marwou de Kock; Hadn Africa; Charlene Barnard; Michele van Rooyen; Lynnett Stone; Catherine Riou; Tobias Kollmann; Thomas R Hawn; Thomas J Scriba; Willem A Hanekom
Journal:  J Immunol       Date:  2014-04-14       Impact factor: 5.422

Review 3.  Tuberculosis vaccine research in China.

Authors:  Douglas B Lowrie
Journal:  Emerg Microbes Infect       Date:  2012-07-25       Impact factor: 7.163

4.  Microphysiologic Human Tissue Constructs Reproduce Autologous Age-Specific BCG and HBV Primary Immunization in vitro.

Authors:  Guzman Sanchez-Schmitz; Chad R Stevens; Ian A Bettencourt; Peter J Flynn; Klaus Schmitz-Abe; Gil Metser; David Hamm; Kristoffer J Jensen; Christine Benn; Ofer Levy
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

Review 5.  Soluble mediators regulating immunity in early life.

Authors:  Matthew Aaron Pettengill; Simon Daniël van Haren; Ofer Levy
Journal:  Front Immunol       Date:  2014-09-24       Impact factor: 7.561

6.  Cancer stem cells as targets for DC-based immunotherapy of colorectal cancer.

Authors:  Magdalena Szaryńska; Agata Olejniczak; Jarosław Kobiela; Dariusz Łaski; Zbigniew Śledziński; Zbigniew Kmieć
Journal:  Sci Rep       Date:  2018-08-13       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.